Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Hard-to-Treat lymphoma: golidocitinib faces final test

NCT ID NCT07234162

Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 3 trial tests a new drug, golidocitinib, against standard treatments for adults with relapsed or refractory peripheral T-cell lymphoma, a rare blood cancer. About 218 participants worldwide will receive either golidocitinib pills or a doctor-chosen drug. The goal is to see if golidocitinib can delay cancer growth better than current options.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
golidocitinib
What this could lead to
If it works, this could offer a new treatment option for people with relapsed or hard-to-treat peripheral T-cell lymphoma.
What could go wrong
This is an early-stage Phase 3 trial, so results may not confirm benefit. Side effects from golidocitinib or comparator drugs could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 218 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The participants should sign the ICF and be able to comply with the relevant requirements in the ICF and protocol * Age ≥ 18 years * ECOG 0-2 score, life expectancy ≥ 12 weeks * Patients must have histologically confirmed peripheral T-cell lymphoma according to the World Health Organization classification of lymphoma. Eligible subtypes are restricted to: PTCL-not otherwise specified, NOS (PTCL, NOS), Angioimmunoblastic T-cell lymphoma (AITL), anaplastic large-cell lymphoma ALK-positive (ALCL ALK+), anaplastic large-cell lymphoma ALK-negative (ALCL ALK-), Follicular T-cell lymphoma, or PTCL with T-follicular helper (TFH) phenotype (FTCL or PTCL-TFH), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Natural killer/T-cell lymphoma (NK/TCL), Hepatosplenic T-cell lymphoma (HSTCL), Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) * Progressed on, were refractory to or intolerant to at least one line of prior standard systemic therapies assessed by investigator * Adequate bone marrow reserve and organ system functions * Willing to comply with contraceptive restrictions Exclusion Criteria: * Any of previous or current treatment prohibited by protocol * Any unresolved \> grade 2 drug-related adverse events * Lymphoma involving central nervous system * Any of severe cardiac or pulmonary abnormalities * Disease condition requires immunosuppressants, biologics, or NSAIDs * Active infection * Malignancy disease within five years * Poorly controlled gastrointestinal disorder or inadequate absorption of medication * Severe or poorly controlled systemic diseases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peripheral T-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Peripheral T-cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    51 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Anhui Provincial Cancer Hospital

    RECRUITING

    Hefei, Anhui, 230000, China

  • Beijing Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100005, China

  • Beijing Tongren Hospital, CMU

    RECRUITING

    Beijing, Beijing Municipality, 100051, China

  • Chang Bing Show Chwan Memorial Hospital

    RECRUITING

    Changhua, 00505, Taiwan

  • Chi Mei Medical Center - Liouying Branch

    RECRUITING

    Tainan, 00736, Taiwan

  • China Medical University Hospital

    RECRUITING

    Taichung, 40447, Taiwan

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350011, China

  • Gansu Provincial Cancer Hospital

    RECRUITING

    Lanzhou, Gansu, 730050, China

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangzhou, Guangdong, 510210, China

  • Guangxi Medical University Cancer Hospital

    RECRUITING

    Nanning, Guangxi, 530200, China

  • Harbin Medical University Cancer Hospital

    RECRUITING

    Harbin, Heilongjiang, 150081, China

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, 450008, China

  • Hubei Cancer Hospital

    RECRUITING

    Wuhan, Hubei, 430079, China

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, 410013, China

  • Jinhua Municipal Centeral Hospital

    RECRUITING

    Jinhua, Zhejiang, 321000, China

  • Kaohsiung Chang Gung Memorial Hospital

    RECRUITING

    Kaohsiung City, 00833, Taiwan

  • King Chulalongkorn Memorial Hospital

    RECRUITING

    Bangkok, 10330, Thailand

  • Koo Foundation Sun Yat-Sen Cancer Center

    RECRUITING

    Taipei, 11259, Taiwan

  • Linyi Cancer Hospital

    RECRUITING

    Linyi, Shandong, 276304, China

  • Maharaj Nakorn Chiang Mai Hospital

    RECRUITING

    Chiang Mai, 50200, Thailand

  • Mahidol University - Faculty of Medicine - Ramathibodi Hospital

    RECRUITING

    Bangkok, 10400, Thailand

  • Nanjing Drum Tower Hospital

    RECRUITING

    Nanjing, Jiangsu, 210008, China

  • National Cheng Kung University Hospital

    RECRUITING

    Tainan, 70403, Taiwan

  • National Taiwan University Hospital

    RECRUITING

    Taipei, 10048, Taiwan

  • Peking University Third Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100191, China

  • Phramongkutklao Hospital

    RECRUITING

    Bangkok, 10400, Thailand

  • Prince of Songkla University-Faculty of Medicine

    RECRUITING

    Hat Yai, 90110, Thailand

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

  • Shandong Cancer Hospital & Institution

    RECRUITING

    Jinan, Shandong, 250117, China

  • Shanxi Provincial Cancer Hospital

    RECRUITING

    Taiyuan, Shanxi, 30013, China

  • Shengjing Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, 110134, China

  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, Sichuan, 610072, China

  • Siriraj Hospital - Mahidol University

    RECRUITING

    Bangkok, 10700, Thailand

  • Srinagarind Hospital - Faculty of Medicine Khon Kaen University

    NOT_YET_RECRUITING

    Khon Kaen, 40002, Thailand

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

  • Taipei Medical University - Shuang Ho Hospital

    RECRUITING

    New Taipei City, 23561, Taiwan

  • The First Affiliated Hospital Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310006, China

  • The First Affiliated Hospital of Chongqing Medical University

    RECRUITING

    Chongqing, Chongqing Municipality, 400016, China

  • The First Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, Zhejiang, 325015, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    RECRUITING

    Xi’an, Shanxi, 710061, China

  • The First Affiliated Hospital of Xiamen University

    RECRUITING

    Xiamen, Fujian, 361026, China

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, 450052, China

  • The First Bethune Hospital of Jilin University

    RECRUITING

    Changchun, Jilin, China

  • The First Hospital of Lanzhou University

    RECRUITING

    Lanzhou, Gansu, 730013, China

  • The Second Hospital of Anhui Medical University

    RECRUITING

    Hefei, Anhui, 230601, China

  • Tianjin Medical University Cancer Institute & Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300060, China

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430030, China

  • Tongji Hospital of Tongji University

    RECRUITING

    Shanghai, Shanghai Municipality, 200065, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430048, China

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, 310022, China

  • Zhongnan Hospital of Wuhan University

    RECRUITING

    Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.